Michael Muhonen

Director at Myrtelle

Capital raised by Myrtelle

$24.2M+$16.7M latest round

2 Form D filings · first filed Mar 2025 · New York, NY

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 4
FOUNDED: 2021
30D INTEREST: 1 ↗

Career

1 company on file · founded 2021

MyrtelleBiotech · New York, NYsince 2021

Director

Listed on Myrtelle's Form D filings

Company filings

via EDGAR · Form D for Myrtelle2

DateCompanyFormAmountRole on filing

Jun 22, 2026MyrtelleForm D+$16.7M—

Form DJun 22, 2026 · Myrtelle+$16.7Mnot a signer

Mar 12, 2025MyrtelleForm D+$7.5M—

Form DMar 12, 2025 · Myrtelle+$7.5Mnot a signer

Overview

Last filing Jun 22, 2026

Michael Muhonen is on file as Director at Myrtelle in New York, NY. Myrtelle has 2 Form D filings on record, $24.2M raised in total.

Teammates

Myrtelle · 3

Adiran StecykChief Executive Officer and DirectorSigner Adrian StecykChief Executive Officer and DirectorSigner Thomas BartonDirector

Products

Myrtelle · 1

rAAV-Olig001-ASPAGene Therapy

rAAV-Olig001-ASPA is an investigational gene therapy specifically designed to treat Canavan disease, a severe childhood genetic disorder characterized by the degeneration of white matter in the brain.